"Together with Microsoft Germany, we aim to advance the future of health insights," says Gloria Seibert, founder and CEO of Temedica. "Linking health-related data and harnessing artificial intelligence opens doors to unprecedented opportunities. We are at the dawn of a new era where Real-World Evidence plays a central role. In a collaborative setting, we will delve deeply into discussions and re-envision real-world insights."
The event will cover a broad range of topics, emphasizing the potential of real-world evidence for medical research, the significance of patient-centricity in today's health landscape, and the evolving dynamics of data-driven market development. Among the confirmed keynote speakers are Prof. Dr. Dr. Sebastian Schneeweiss, Professor of Medicine and Epidemiology at Harvard Medical School, Dr. Stefan Oschmann, former Chairman and CEO of the Merck Group, Marianne Janik, CEO of Microsoft Germany, and Dr. Leonard Achenbach, team physician of FC Bayern Munich.
In a time where digitization and artificial intelligence are molding the future of the healthcare sector, Temedica aims to offer a platform where industry frontrunners can unite to explore the potential of health data. The key to advancement is in the transition from raw data to actionable insights, and in adjusting the factors that drive this evolution.
For further details about the event and for registration, visit our website at https://temedica.com/en/temedica-future-of-health-insights-2023.
About Temedica
Temedica is a health insights company based in Munich. Since 2016, it operates Europe's leading ecosystem for real-world insights in the healthcare sector. Temedica's mission is to enable personalized and individualized medicine, thereby focusing on patients and their individual needs. The company achieves this by linking health-related data from various sources, which are processed into valuable insights in compliance with the GDPR.
Temedica is backed by a consortium of renowned investors with many years of experience in the biopharmaceutical industry, including the founding investors of BioNTech. For further information, please visit https://temedica.com/en/.
For further information and media inquiries, please contact:
Anna Hauner
Corporate Communications
Phone: + 49 (0) 175 431 030 1
Mail: pr@temedica.com